COMP <GO>
RDY vs BBIO // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Dr. Reddy's Laboratories Ltd (NYSE) VS. BridgeBio Pharma Inc. (NASDAQ) • 15-METRIC TALLY: RDY 9
— BBIO 2
■ METRIC PARITY
LAST: $14.13 (-0.28%) • MKT CAP: $11.83B
options-implied-move
—
LAST: $75.00 (+0.06%) • MKT CAP: $14.60B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RDY VS. BBIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RDY | BBIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 95.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | -35.00% | +44.90 | RDY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | -3.23% | +5.44 | RDY | /fcf-yield <GO> |
| Operating Margin | 13.90% | -60.00% | +73.90 | RDY | /operating-margins <GO> |
| Net Profit Margin | 10.90% | -60.00% | +70.90 | RDY | /net-margins <GO> |
| Revenue Growth (YoY) | 6.60% | 126.30% | -119.70 | BBIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 0.45 | +3.29 | RDY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 4/9 | +4.00 | RDY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 76.2 | 63.9 | +12.30 | RDY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.00 | +0.05 | RDY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.5x | 33.0x | -2.50 | RDY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.83B | $14.60B | -$2.77B | BBIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RDY REV | BBIO REV | RDY GROSS % | BBIO GROSS % | RDY FCF | BBIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $502.1M | — | 95.8% | — | -$447.0M |
| FY 2024 | — | $221.9M | — | 98.3% | — | -$521.7M |
| FY 2023 | — | $9.3M | — | — | — | -$528.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RDY // BETA 1.05
BBIO // BETA 1.00